prazosin has been researched along with Body Weight in 80 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 12-week double-blind study was performed to compare the safety and efficacy of doxazosin, prazosin and placebo in 172 patients with essential hypertension." | 9.06 | Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. ( Madsbu, HP; Torvik, D, 1986) |
| "The long-term treatment of essential hypertension with terazosin, a new once-a-day alpha 1-adrenergic blocking agent, was evaluated in 364 hypertensive patients who received total daily doses of 1 to 40 mg for 3 weeks to 56 months." | 9.06 | Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension. ( Estep, CB; Glassman, HN; Horton, JK; Jordan, DC; Luther, RR; Schmitz, PJ, 1988) |
| "The efficacy and tolerability of felodipine and prazosin were compared in a double-blind randomised parallel group study of 100 patients with moderately severe essential hypertension, treated concomitantly with a beta-blocking drug." | 9.06 | Felodipine versus prazosin as an addition to a beta-blocker in the treatment of essential hypertension. The Australian Multicentre Study. ( Anderson, A; Gibson, J; Jackson, B; Morgan, TO, 1987) |
| "Patients with essential hypertension were randomized to treatment with either prazosin or pinacidil, a new direct-acting vasodilator." | 9.06 | Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension. ( Solomon, RJ; Weinberg, MS, 1987) |
| "Chronic responses of systemic hemodynamics and blood pressure counterregulatory ("pseudo-tolerance") mechanisms were investigated in matched groups of patients with essential hypertension after 1 month of vasodilator therapy with pinacidil (a direct arterial dilator), prazosin (an alpha 1-adrenergic blocking drug) or captopril (an angiotensin-converting enzyme inhibitor)." | 9.06 | Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension. ( Izzo, JL; Kallay, MC; Larrabee, PS; Licht, MR; Radke, KJ; Smith, RJ, 1987) |
| "In a multicenter, double-blind, placebo-controlled study, the efficacy and safety of terazosin and prazosin were compared in patients with mild to moderate essential hypertension." | 9.06 | Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension. ( Deger, G, 1986) |
| "The safety and efficacy of once-daily terazosin as monotherapy were evaluated in five randomized, double-blind, placebo-controlled studies in which 351 patients with mild to moderate hypertension participated." | 9.06 | Terazosin: an effective once-daily monotherapy for the treatment of hypertension. ( Dauer, AD, 1986) |
| "The stimulus for carbon monoxide-induced cardiac hypertrophy was investigated." | 7.68 | Carbon monoxide-induced cardiac hypertrophy is not reduced by alpha- or beta-blockade in the rat. ( Formolo, JM; Penney, DG, 1993) |
| "Two hundred twenty-six patients with mild to moderate hypertension were treated with terazosin in an open, multicenter study to determine the drug's long-term efficacy and safety." | 7.67 | Long-term experience with terazosin for treatment of mild to moderate hypertension. ( Mersey, JH, 1986) |
| "Prazosin was used as additional therapy in seven patients with severe chronic congestive cardiac failure." | 7.66 | Effect of prazosin on renal function in chronic congestive cardiac failure. ( Morgan, TO; Myers, JB; Walker, JN, 1981) |
| "There is evidence that cardiac hypertrophy in spontaneously hypertensive rats (SHR) occurs before the development of hypertension." | 5.28 | Enalapril reduces the enhanced 1,2-diacylglycerol content and RNA synthesis in spontaneously hypertensive rat hearts before established hypertension. ( Asano, H; Hashimoto, H; Ishikawa, K; Ito, T; Kondo, J; Okumura, K; Yoshino, M, 1992) |
| "Patients with essential hypertension were randomized to treatment with either prazosin or pinacidil, a new direct-acting vasodilator." | 5.06 | Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension. ( Solomon, RJ; Weinberg, MS, 1987) |
| "A 12-week double-blind study was performed to compare the safety and efficacy of doxazosin, prazosin and placebo in 172 patients with essential hypertension." | 5.06 | Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. ( Madsbu, HP; Torvik, D, 1986) |
| "The long-term treatment of essential hypertension with terazosin, a new once-a-day alpha 1-adrenergic blocking agent, was evaluated in 364 hypertensive patients who received total daily doses of 1 to 40 mg for 3 weeks to 56 months." | 5.06 | Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension. ( Estep, CB; Glassman, HN; Horton, JK; Jordan, DC; Luther, RR; Schmitz, PJ, 1988) |
| "The efficacy and tolerability of felodipine and prazosin were compared in a double-blind randomised parallel group study of 100 patients with moderately severe essential hypertension, treated concomitantly with a beta-blocking drug." | 5.06 | Felodipine versus prazosin as an addition to a beta-blocker in the treatment of essential hypertension. The Australian Multicentre Study. ( Anderson, A; Gibson, J; Jackson, B; Morgan, TO, 1987) |
| "Chronic responses of systemic hemodynamics and blood pressure counterregulatory ("pseudo-tolerance") mechanisms were investigated in matched groups of patients with essential hypertension after 1 month of vasodilator therapy with pinacidil (a direct arterial dilator), prazosin (an alpha 1-adrenergic blocking drug) or captopril (an angiotensin-converting enzyme inhibitor)." | 5.06 | Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension. ( Izzo, JL; Kallay, MC; Larrabee, PS; Licht, MR; Radke, KJ; Smith, RJ, 1987) |
| "In a multicenter, double-blind, placebo-controlled study, the efficacy and safety of terazosin and prazosin were compared in patients with mild to moderate essential hypertension." | 5.06 | Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension. ( Deger, G, 1986) |
| "The safety and efficacy of once-daily terazosin as monotherapy were evaluated in five randomized, double-blind, placebo-controlled studies in which 351 patients with mild to moderate hypertension participated." | 5.06 | Terazosin: an effective once-daily monotherapy for the treatment of hypertension. ( Dauer, AD, 1986) |
| " Addition of eugenosedin-A to the high-fat diet resulted in less weight gain and reduced hyperglycaemia, hyperinsulinaemia and hyperlipidaemia." | 3.75 | Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet. ( Chen, IJ; Hsieh, SL; Kwan, AL; Lin, HL; Shen, KP; Wu, BN, 2009) |
| "A novel model of hypertension recently developed in our laboratory shows that neonatal degeneration of capsaicin-sensitive sensory nerves renders a rat responsive to a salt load with a significant rise in blood pressure." | 3.70 | Antihypertensive mechanisms underlying a novel salt-sensitive hypertensive model induced by sensory denervation. ( Li, J; Wang, DH, 1999) |
| "The stimulus for carbon monoxide-induced cardiac hypertrophy was investigated." | 3.68 | Carbon monoxide-induced cardiac hypertrophy is not reduced by alpha- or beta-blockade in the rat. ( Formolo, JM; Penney, DG, 1993) |
| "The development of cardiac hypertrophy was examined in rats given ethanol in a nutritionally adequate, liquid diet mixture, by intubation, in severely intoxicating doses at 8-h intervals for up to 96 h, alone or in combination with prazosin." | 3.67 | Lack of cardiac alpha 1-adrenoceptor involvement in ethanol-induced cardiac hypertrophy. ( Adams, MA; Hirst, M, 1989) |
| "The current study was designed to explore the effects of peripherally administered alpha-adrenoceptor inhibiting drugs (either prazosin or yohimbine) in spontaneously hypertensive (SHR) and DOCA-salt hypertensive rats before the development of established hypertension, as well as to characterize changes induced by prazosin and/or yohimbine in the cardiac noradrenaline (NA) content that might be responsible for the development of hypertension in these strains." | 3.67 | Alpha-blockade on blood pressure and on cardiac noradrenaline content in SHR and DOCA-salt rats. ( Saiz, J; Sanchez, A; Torres, A, 1989) |
| "Two hundred twenty-six patients with mild to moderate hypertension were treated with terazosin in an open, multicenter study to determine the drug's long-term efficacy and safety." | 3.67 | Long-term experience with terazosin for treatment of mild to moderate hypertension. ( Mersey, JH, 1986) |
| "The safety of terazosin, an effective agent for the treatment of hypertension, was assessed by analyzing data from 1,006 hypertensive patients who were enrolled in short-term and/or long-term studies." | 3.67 | Overall safety of terazosin as an antihypertensive agent. ( Glassman, HN; Jordan, DC; Luther, RR; Sperzel, WD, 1986) |
| "Prazosin was used as additional therapy in seven patients with severe chronic congestive cardiac failure." | 3.66 | Effect of prazosin on renal function in chronic congestive cardiac failure. ( Morgan, TO; Myers, JB; Walker, JN, 1981) |
| "Seventeen patients with newly diagnosed hypertension, or with hypertension not optimally controlled by previous treatment, completed an open, noncomparative study on the effects of prazosin on plasma lipids." | 3.66 | Open assessment of the effect of prazosin on plasma lipids. ( Flax, JS; Havard, CW; Khokhar, AM, 1982) |
| "In a dose-response study of prazosin in 24 patients with Raynaud's phenomenon, the clinical effectiveness and side effects of 3, 6, and 12 mg prazosin administered daily were compared." | 2.66 | Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side effects. ( Thien, T; Wollersheim, H, 1988) |
| "Treatment with prazosin, an α1-adrenergic antagonist and vasodilator, increased tail temperature in control mice by up to 4." | 1.56 | The contribution of the mouse tail to thermoregulation is modest. ( Gavrilova, O; Guo, J; Liu, N; Reitman, ML; Škop, V, 2020) |
| "Prazosin was used as a reference compound, as quinazoline-based α1-adrenolytics may potentially exert unfavorable proapoptotic and necrotic effects." | 1.51 | Reversal of cardiac, vascular, and renal dysfunction by non-quinazoline α1-adrenolytics in DOCA-salt hypertensive rats: a comparison with prazosin, a quinazoline-based α1-adrenoceptor antagonist. ( Filipek, B; Kotańska, M; Kubacka, M; Marona, H; Mogilski, S; Nowak, B; Waszkielewicz, AM; Zadrożna, M, 2019) |
| "Tesofensine is a novel monoamine reuptake inhibitor that inhibits both norepinephrine, 5-HT, and dopamine (DA) reuptake function." | 1.36 | Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. ( Axel, AM; Hansen, HH; Mikkelsen, JD, 2010) |
| "Morphine withdrawal was precipitated by administration of naloxone (5 mg/kg subcutaneously) on day 8." | 1.32 | Changes in c-fos expression in the rat heart during morphine withdrawal. Involvement of alpha2-adrenoceptors. ( Aviles, M; González-Cuello, A; Laorden, ML; Milanés, MV, 2004) |
| "Hydralazine was the only drug to alter the lipid peroxidation level in the myocardium of SHR rats (a 28% decrease), but in WKY rats all three drugs caused significant decreases in myocardial lipid peroxidation levels." | 1.30 | Effects of antihypertensive drugs on rat tissue antioxidant enzyme activities and lipid peroxidation levels. ( Cabell, KS; Johnson, P; Ma, L, 1997) |
| "High sodium diet (HS, 8% NaCl) induces left ventricular hypertrophy (LVH) in normotensive rats without an increase in pressure or volume load or in resting cardiac sympathetic activity." | 1.30 | alpha- and beta-adrenoceptor blockade fail to prevent high sodium diet-induced left ventricular hypertrophy. ( Harmsen, E; Leenen, FH; Song, D, 1997) |
| " The dose-response relationship of cocaine with fetal development was established in CF-1 mice by administering cocaine sc on days 5 to 18 of gestation followed by teratologic evaluation." | 1.28 | Antagonism of cocaine-induced fetal anomalies by prazosin and diltiazem in mice. ( Hitner, HW; Mahalik, MP, 1992) |
| " In both the SHR and WKY, chronic administration of terazosin did not influence vascular concentrations of 3-methylhistidine, a biochemical marker for contractile proteins and vascular medial hypertrophy." | 1.28 | Effect of alpha 1-adrenoceptor blockade on the development of hypertension in the spontaneously hypertensive rat. ( Frewin, DB; Head, RJ; Jonsson, JR, 1992) |
| "There is evidence that cardiac hypertrophy in spontaneously hypertensive rats (SHR) occurs before the development of hypertension." | 1.28 | Enalapril reduces the enhanced 1,2-diacylglycerol content and RNA synthesis in spontaneously hypertensive rat hearts before established hypertension. ( Asano, H; Hashimoto, H; Ishikawa, K; Ito, T; Kondo, J; Okumura, K; Yoshino, M, 1992) |
| "Doxazosin treatment partially prevented the accumulation of cholesterol and triglycerides in the liver." | 1.28 | Effects of the selective alpha 1-antagonist, doxazosin, on hepatic lipid levels and metabolism in the golden hamster. ( Birkenhäger, JC; Jansen, H, 1991) |
| "Treatment with prazosin, an alpha 1-noradrenergic receptor antagonist, reduced Na+-K+-ATPase in either control or cafeteria diet-fed rats but did not alter the effect of cafeteria diet feeding." | 1.27 | Caloric intake and Na+-K+-ATPase: differential regulation by alpha 1- and beta-noradrenergic receptors. ( Swann, AC, 1984) |
| " When administered daily for 1 month at dosages of 0, 10, 40 or 150 mg/kg/day, the no-toxic-effect dosage was 40 mg/kg/day." | 1.27 | Terazosin: intravenous safety evaluation in rats. ( Cusick, PK; Fort, FL; Heyman, IA; Kesterson, JW; Majors, K; Tekeli, S, 1984) |
| "Renal hypertrophy was also decreased significantly by cicletanine at a dose of 100 mg/kg." | 1.27 | Comparison of cicletanine with other antihypertensive drugs in SHR-SP models. ( Braquet, P; Clostre, F; Le Hegarat, M; Malherbe, E, 1988) |
| "Yohimbine was without effect in androgenized and nonandrogenized animals." | 1.27 | Postnatal treatment of rats with adrenergic receptor agonists or antagonists influences differentiation of sexual behavior. ( Döhler, KD; Geerlings, H; Jarzab, B; Sickmöller, PM, 1987) |
| "Prazosin was given after clonidine to the same patients in a dose range of 3 to 40 mg/day." | 1.26 | Clonidine and prazosin effects in hypernoradrenergic vasodilator-treated and beta-blocker-treated patients. ( Mitchell, HC; Pettinger, WA, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (42.50) | 18.7374 |
| 1990's | 27 (33.75) | 18.2507 |
| 2000's | 13 (16.25) | 29.6817 |
| 2010's | 5 (6.25) | 24.3611 |
| 2020's | 1 (1.25) | 2.80 |
| Authors | Studies |
|---|---|
| Škop, V | 1 |
| Liu, N | 1 |
| Guo, J | 1 |
| Gavrilova, O | 1 |
| Reitman, ML | 1 |
| Kubacka, M | 1 |
| Zadrożna, M | 1 |
| Nowak, B | 1 |
| Kotańska, M | 1 |
| Filipek, B | 1 |
| Waszkielewicz, AM | 1 |
| Marona, H | 1 |
| Mogilski, S | 1 |
| Vickers, SP | 1 |
| Hackett, D | 1 |
| Murray, F | 1 |
| Hutson, PH | 1 |
| Heal, DJ | 1 |
| Shen, KP | 1 |
| Lin, HL | 1 |
| Hsieh, SL | 1 |
| Kwan, AL | 1 |
| Chen, IJ | 1 |
| Wu, BN | 1 |
| Axel, AM | 1 |
| Mikkelsen, JD | 1 |
| Hansen, HH | 1 |
| White, CW | 1 |
| Short, JL | 1 |
| Haynes, JM | 1 |
| Matsui, M | 1 |
| Ventura, S | 1 |
| Kristek, F | 1 |
| Koprdova, R | 1 |
| Papay, R | 1 |
| Zuscik, MJ | 1 |
| Ross, SA | 1 |
| Yun, J | 1 |
| McCune, DF | 1 |
| Gonzalez-Cabrera, P | 1 |
| Gaivin, R | 1 |
| Drazba, J | 1 |
| Perez, DM | 1 |
| Zaninovich, AA | 1 |
| Rebagliati, I | 1 |
| Raices, M | 1 |
| Ricci, C | 1 |
| Hagmuller, K | 1 |
| Oben, JA | 1 |
| Roskams, T | 1 |
| Yang, S | 1 |
| Lin, H | 1 |
| Sinelli, N | 1 |
| Li, Z | 1 |
| Torbenson, M | 1 |
| Huang, J | 1 |
| Guarino, P | 1 |
| Kafrouni, M | 1 |
| Diehl, AM | 1 |
| González-Cuello, A | 1 |
| Milanés, MV | 1 |
| Aviles, M | 1 |
| Laorden, ML | 1 |
| Farah, V | 1 |
| Elased, KM | 1 |
| Chen, Y | 1 |
| Key, MP | 1 |
| Cunha, TS | 1 |
| Irigoyen, MC | 1 |
| Morris, M | 1 |
| Pérez, H | 2 |
| Ruiz, S | 2 |
| Núñez, H | 2 |
| White, A | 2 |
| Gotteland, M | 2 |
| Hernández, A | 1 |
| Tsai, YS | 1 |
| Tong, YC | 1 |
| Cheng, JT | 1 |
| Lee, CH | 1 |
| Yang, FS | 1 |
| Lee, HY | 1 |
| Latifpour, J | 1 |
| McNeill, JH | 1 |
| Swann, AC | 1 |
| Raasmaja, A | 1 |
| Mohell, N | 1 |
| Nedergaard, J | 1 |
| Mitchell, HC | 1 |
| Pettinger, WA | 1 |
| Havard, CW | 1 |
| Khokhar, AM | 1 |
| Flax, JS | 1 |
| Williams, RS | 1 |
| Schaible, TF | 1 |
| Scheuer, J | 1 |
| Kennedy, R | 1 |
| Mills, PR | 1 |
| Rae, AP | 1 |
| Farah, DA | 1 |
| Russell, RI | 1 |
| Lorimer, AR | 1 |
| Carter, DC | 1 |
| Fort, FL | 1 |
| Tekeli, S | 1 |
| Majors, K | 1 |
| Heyman, IA | 1 |
| Cusick, PK | 1 |
| Kesterson, JW | 1 |
| Vardan, S | 1 |
| Smulyan, H | 1 |
| Mookherjee, S | 1 |
| Eich, R | 1 |
| Myers, JB | 1 |
| Morgan, TO | 2 |
| Walker, JN | 1 |
| Imai, C | 1 |
| Tozawa, M | 1 |
| Sunagawa, O | 1 |
| Muratani, H | 1 |
| Takishita, S | 1 |
| Fukiyama, K | 1 |
| Nagano, T | 1 |
| O'Harrow, S | 1 |
| Sponer, G | 1 |
| Zimmer, HG | 1 |
| Semplicini, A | 1 |
| Valle, R | 1 |
| Serena, L | 1 |
| Fazari, G | 1 |
| Fontebasso, A | 1 |
| Gebbin, A | 1 |
| De Toni, R | 1 |
| Pessina, AC | 1 |
| Penner, SB | 2 |
| Jeffery, JJ | 1 |
| Smyth, DD | 2 |
| Stanko, CK | 1 |
| Penney, DG | 1 |
| Formolo, JM | 1 |
| Skúladóttir, GV | 1 |
| Schiöth, HB | 1 |
| Gudbjarnason, S | 1 |
| Levin, BE | 1 |
| Planas, B | 1 |
| Routh, VH | 1 |
| Hamilton, J | 1 |
| Stern, JS | 1 |
| Horwitz, BA | 1 |
| Okuyama, N | 1 |
| Morinobu, S | 1 |
| Totsuka, S | 1 |
| Endoh, M | 1 |
| Sallés, J | 1 |
| Gascón, S | 1 |
| Badia, A | 1 |
| Takada, S | 1 |
| Numabe, A | 1 |
| Hirawa, N | 1 |
| Yagi, S | 1 |
| Uehara, Y | 1 |
| Chen, C | 1 |
| Noland, KA | 1 |
| Kalu, DN | 1 |
| Song, D | 1 |
| Harmsen, E | 1 |
| Leenen, FH | 2 |
| Cabell, KS | 1 |
| Ma, L | 1 |
| Johnson, P | 1 |
| Wang, DH | 1 |
| Li, J | 1 |
| Obrosova, IG | 1 |
| Van Huysen, C | 1 |
| Fathallah, L | 1 |
| Cao, X | 1 |
| Stevens, MJ | 1 |
| Greene, DA | 1 |
| Tropia, FC | 1 |
| Cardoso, LM | 1 |
| Pedrosa, ML | 1 |
| Silva, ME | 1 |
| Haibara, AS | 1 |
| Moraes, MF | 1 |
| Chianca, DA | 1 |
| Abete, P | 1 |
| Testa, G | 1 |
| Ferrara, N | 1 |
| De Santis, D | 1 |
| Capaccio, P | 1 |
| Viati, L | 1 |
| Calabrese, C | 1 |
| Cacciatore, F | 1 |
| Longobardi, G | 1 |
| Condorelli, M | 1 |
| Napoli, C | 1 |
| Rengo, F | 1 |
| Brown, RA | 1 |
| Ilg, KJ | 1 |
| Chen, AF | 1 |
| Ren, J | 1 |
| Keusch, G | 1 |
| Weidmann, P | 2 |
| Glück, Z | 1 |
| Meier, A | 1 |
| Beretta-Piccoli, C | 1 |
| Jonsson, JR | 1 |
| Head, RJ | 1 |
| Frewin, DB | 1 |
| Okumura, K | 1 |
| Kondo, J | 1 |
| Yoshino, M | 1 |
| Ishikawa, K | 1 |
| Asano, H | 1 |
| Hashimoto, H | 2 |
| Ito, T | 1 |
| Fitch, RH | 1 |
| Feder, H | 1 |
| Mahalik, MP | 1 |
| Hitner, HW | 1 |
| Ferrari, P | 1 |
| Rosman, J | 1 |
| Neuner, N | 1 |
| Shaw, S | 1 |
| Riesen, W | 1 |
| Jansen, H | 1 |
| Birkenhäger, JC | 1 |
| Inazu, M | 1 |
| Sakai, Y | 1 |
| Homma, I | 1 |
| Jansson, JH | 1 |
| Johansson, B | 1 |
| Boman, K | 1 |
| Nilsson, TK | 1 |
| Nakamoto, H | 1 |
| Suzuki, H | 1 |
| Kageyama, Y | 1 |
| Ohishi, A | 1 |
| Murakami, M | 1 |
| Naitoh, M | 1 |
| Saruta, T | 1 |
| Klement, G | 1 |
| Pérez-Olea, J | 1 |
| Prat, H | 1 |
| Román, O | 2 |
| Zarate, LH | 1 |
| Cabello, H | 1 |
| Quevedo, M | 1 |
| Fuentes, S | 1 |
| Reinback, R | 1 |
| Chadid, P | 1 |
| Itaya, T | 1 |
| Satoh, R | 1 |
| Uematsu, T | 1 |
| Nakashima, M | 1 |
| Bitar, M | 1 |
| Koulu, M | 1 |
| Rapoport, SI | 1 |
| Linnoila, M | 1 |
| Ames, RP | 1 |
| Chrysant, SG | 1 |
| Gonzalez, F | 1 |
| Schnaper, HW | 1 |
| Spann, S | 1 |
| Velasquez, MT | 1 |
| Adams, MA | 1 |
| Hirst, M | 1 |
| Sanchez, A | 2 |
| Torres, A | 2 |
| Saiz, J | 2 |
| Ziada, A | 1 |
| Hudlicka, O | 1 |
| Tyler, KR | 1 |
| Kaschube, M | 1 |
| Möller-Hartmann, H | 1 |
| Zetler, G | 1 |
| Lara, B | 1 |
| Geller, HS | 1 |
| Nyhan, DP | 1 |
| Goll, HM | 1 |
| Clougherty, PW | 1 |
| Chen, BB | 1 |
| Murray, PA | 1 |
| Dauer, AD | 1 |
| Deger, G | 1 |
| Mersey, JH | 1 |
| Sperzel, WD | 1 |
| Glassman, HN | 2 |
| Jordan, DC | 2 |
| Luther, RR | 2 |
| Izzo, JL | 1 |
| Licht, MR | 1 |
| Smith, RJ | 1 |
| Larrabee, PS | 1 |
| Radke, KJ | 1 |
| Kallay, MC | 1 |
| Jarzab, B | 1 |
| Sickmöller, PM | 1 |
| Geerlings, H | 1 |
| Döhler, KD | 1 |
| Jackson, B | 1 |
| Gibson, J | 1 |
| Anderson, A | 1 |
| Estep, CB | 1 |
| Schmitz, PJ | 1 |
| Horton, JK | 1 |
| Nafstad, I | 1 |
| Tollersrud, S | 1 |
| Eriksen, K | 1 |
| Helgeland, A | 1 |
| Solberg, LA | 1 |
| Bredesen, J | 1 |
| Dale, O | 1 |
| Torvik, D | 1 |
| Madsbu, HP | 1 |
| Malherbe, E | 1 |
| Le Hegarat, M | 1 |
| Clostre, F | 1 |
| Braquet, P | 1 |
| McCaughran, JA | 1 |
| Juno, CJ | 1 |
| Friedman, R | 1 |
| Wollersheim, H | 1 |
| Thien, T | 1 |
| Solomon, RJ | 1 |
| Weinberg, MS | 1 |
| Sulakhe, SJ | 1 |
12 trials available for prazosin and Body Weight
| Article | Year |
|---|---|
Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension.
Topics: Atenolol; Blood Pressure; Body Weight; Clinical Trials as Topic; Female; Heart Rate; Humans; Hyperte | 1984 |
Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Double-Blind Method; Doxazosi | 1991 |
[The antihypertensive response to prazosin, a selective vascular alpha blocker. A multicenter study].
Topics: Adult; Aged; Blood Pressure; Body Weight; Chi-Square Distribution; Chile; Female; Humans; Hypertensi | 1990 |
Effectiveness of doxazosin in systemic hypertension.
Topics: Adult; Antihypertensive Agents; Body Weight; Double-Blind Method; Doxazosin; Drug Administration Sch | 1989 |
Terazosin: an effective once-daily monotherapy for the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Do | 1986 |
Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Do | 1986 |
Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensiv | 1987 |
Felodipine versus prazosin as an addition to a beta-blocker in the treatment of essential hypertension. The Australian Multicentre Study.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials a | 1987 |
Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Female; Humans; Hypertension | 1988 |
Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Body Weight; Clinical Trials as Topic; Double-Blind Method; Do | 1986 |
Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side effects.
Topics: Adolescent; Adult; Aged; Blood Pressure; Body Weight; Dose-Response Relationship, Drug; Female; Fing | 1988 |
Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials as To | 1987 |
68 other studies available for prazosin and Body Weight
| Article | Year |
|---|---|
The contribution of the mouse tail to thermoregulation is modest.
Topics: Adrenergic alpha-1 Receptor Antagonists; Amputation, Surgical; Animals; Body Composition; Body Surfa | 2020 |
Reversal of cardiac, vascular, and renal dysfunction by non-quinazoline α1-adrenolytics in DOCA-salt hypertensive rats: a comparison with prazosin, a quinazoline-based α1-adrenoceptor antagonist.
Topics: Adrenergic alpha-1 Receptor Agonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; | 2019 |
Effects of lisdexamfetamine in a rat model of binge-eating.
Topics: Animals; Baclofen; Behavior, Animal; Benzazepines; Benzodiazepines; Body Weight; Bulimia; Disease Mo | 2015 |
Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet.
Topics: Adipose Tissue; Animals; Atorvastatin; Blood Glucose; Body Weight; Brain; Dietary Fats; Female; Glut | 2009 |
Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.
Topics: Adrenergic alpha-Antagonists; Animals; Appetite Depressants; Benzazepines; Body Weight; Bridged Bicy | 2010 |
Contractions of the mouse prostate elicited by acetylcholine are mediated by M(3) muscarinic receptors.
Topics: Acetylcholine; Adrenergic alpha-1 Receptor Antagonists; Animals; Benzofurans; Body Weight; Carbachol | 2011 |
Long-term effect of prazosin administration on blood pressure, heart and structure of coronary artery of young spontaneously hypertensive rats.
Topics: Acetylcholine; Adrenergic alpha-1 Receptor Antagonists; Animals; Blood Pressure; Blood Pressure Dete | 2011 |
Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation.
Topics: Adrenergic alpha-Antagonists; alpha-Synuclein; Animals; Body Weight; Brain; Cerebellum; Disease Mode | 2002 |
Mitochondrial respiration in muscle and liver from cold-acclimated hypothyroid rats.
Topics: Adipose Tissue, Brown; Adrenergic Antagonists; Adrenergic Uptake Inhibitors; Animals; Body Weight; C | 2003 |
Sympathetic nervous system inhibition increases hepatic progenitors and reduces liver injury.
Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Body Weight; Diet; Fatty Liver; Hepatocytes; Li | 2003 |
Changes in c-fos expression in the rat heart during morphine withdrawal. Involvement of alpha2-adrenoceptors.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Blotting, Western; Body Weight; Drug Administratio | 2004 |
Nocturnal hypertension in mice consuming a high fructose diet.
Topics: Adrenergic alpha-Antagonists; Angiotensin II; Animals; Blood Glucose; Body Weight; Brain Stem; Circa | 2006 |
Paraventricular-coerulear interactions: role in hypertension induced by prenatal undernutrition in the rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Corticotropin-Releasing Hormone; Diet | 2006 |
Pumpkin seed oil and phytosterol-F can block testosterone/prazosin-induced prostate growth in rats.
Topics: Animals; Body Weight; Cucurbita; Disease Models, Animal; Drug Therapy, Combination; Male; Phytostero | 2006 |
Coerulear activation by crh and its role in hypertension induced by prenatal malnutrition in the rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Corticosterone; Corticotropin-Releasi | 2007 |
Cardiac autonomic receptors: effect of long-term experimental diabetes.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Dihydroalprenolol; Heart; Kinetics; Lung; Mal | 1984 |
Caloric intake and Na+-K+-ATPase: differential regulation by alpha 1- and beta-noradrenergic receptors.
Topics: 4-Nitrophenylphosphatase; Adipose Tissue, Brown; Animals; Body Weight; Desipramine; Diet; Eating; En | 1984 |
Increased alpha 1-adrenergic receptor density in brown adipose tissue of cafeteria-fed rats.
Topics: Adipose Tissue, Brown; Animals; Body Weight; Feeding Behavior; Female; Kinetics; Prazosin; Rats; Rat | 1984 |
Clonidine and prazosin effects in hypernoradrenergic vasodilator-treated and beta-blocker-treated patients.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Body Weight; Clonidine; Diastole; Diuretics; Female; Hu | 1981 |
Open assessment of the effect of prazosin on plasma lipids.
Topics: Adult; Blood Pressure; Body Weight; Cholesterol; Cholesterol, HDL; Female; Heart Rate; Humans; Hyper | 1982 |
Effects of experimental diabetes on adrenergic and cholinergic receptors of rat myocardium.
Topics: Animals; Blood Glucose; Body Weight; Cell Membrane; Diabetes Mellitus, Experimental; Diet, Diabetic; | 1983 |
Terazosin: intravenous safety evaluation in rats.
Topics: Animals; Antihypertensive Agents; Blepharoptosis; Body Temperature; Body Weight; Dose-Response Relat | 1984 |
Effects of tiodazosin, a new antihypertensive, hemodynamics and clinical variables.
Topics: Adult; Blood Chemical Analysis; Blood Pressure; Body Weight; Cardiac Output; Drug Evaluation; Electr | 1983 |
Effect of prazosin on renal function in chronic congestive cardiac failure.
Topics: Adult; Aged; Body Weight; Creatinine; Gout; Heart Failure; Humans; Kidney; Male; Middle Aged; Prazos | 1981 |
Alterations of alpha 1-adrenergic receptor densities in right and left ventricles of spontaneously hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Body Weight; Dogs; Heart Ventricles; Hyperten | 1995 |
Norepinephrine-induced changes in rat heart function, metabolism, and weight are antagonized by carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Body Weight; Carbazoles; Carvedilol; Female; Glucosephosphate | 1993 |
Long-term alpha-1 adrenoceptor blockade does not affect plasma atrial natriuretic peptide in hypertensive patients.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Atrial Natriuretic Fac | 1994 |
Cyclosporine-induced nephrotoxicity in the rat. The effect of alpha 1-adrenoceptor blockade with prazosin.
Topics: Animals; Body Weight; Cyclosporine; Kidney; Kidney Transplantation; Male; Prazosin; Rats; Rats, Spra | 1993 |
Selective alpha-1 adrenoceptor blockade and renal sodium handling in humans.
Topics: Adult; Blood Pressure; Body Weight; Diuresis; Female; Humans; Infusions, Intravenous; Kidney; Kidney | 1993 |
Carbon monoxide-induced cardiac hypertrophy is not reduced by alpha- or beta-blockade in the rat.
Topics: Animals; Atenolol; Blood Pressure; Body Weight; Carbon Monoxide; Cardiomegaly; Heart Rate; Lung; Mal | 1993 |
Polyunsaturated fatty acids in heart muscle and alpha 1-adrenoceptor binding properties.
Topics: Animals; Binding Sites; Body Weight; Dihydroalprenolol; Epinephrine; Fatty Acids, Unsaturated; Hydro | 1993 |
Altered alpha 1-adrenoceptor binding in intact and adrenalectomized obese Zucker rats (fa/fa).
Topics: Adipose Tissue; Adrenalectomy; Animals; Autoradiography; Body Weight; Brain Chemistry; Genotype; Mal | 1993 |
Enhancement of 5-hydroxytryptamine-stimulated phosphoinositide hydrolysis in the rat cerebral cortex by repeated immobilization stress.
Topics: Animals; Body Weight; Cerebral Cortex; Hydrolysis; Imipramine; Immobilization; Ketanserin; Male; Pho | 1995 |
Sustained increase in rat myocardial alpha 1A-adrenoceptors induced by 6-hydroxydopamine treatment involves a decelerated receptor turnover.
Topics: Adrenergic Agents; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Body Weight; Dioxane | 1996 |
Thromboxane inhibition potentiates antihypertensive effects of alpha 1 adrenoceptor antagonists in the rat.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Body Weight; | 1997 |
Effects of aging and food restriction on alpha 1-adrenergic receptors and G-protein in the rat parotid gland.
Topics: Aging; Animals; Binding, Competitive; Body Weight; Cell Membrane; Eating; Epinephrine; Food Deprivat | 1997 |
alpha- and beta-adrenoceptor blockade fail to prevent high sodium diet-induced left ventricular hypertrophy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Body Weight; Dri | 1997 |
Effects of antihypertensive drugs on rat tissue antioxidant enzyme activities and lipid peroxidation levels.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Captopril; Enzyme Activation; Heart; | 1997 |
Antihypertensive mechanisms underlying a novel salt-sensitive hypertensive model induced by sensory denervation.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Blood Pressure; Body Weight; Calcitonin Gene-Rel | 1999 |
Evaluation of alpha(1)-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Blood Glucose; Blood Pressure; Body Weight; Cre | 2000 |
Effects of low-protein diet on the baroreflex and Bezold-Jarisch reflex in conscious rats.
Topics: Afferent Pathways; Animals; Baroreflex; Blood Pressure; Body Weight; Cardiovascular Physiological Ph | 2001 |
Cardioprotective effect of ischemic preconditioning is preserved in food-restricted senescent rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Aging; Animals; Blood Flow Velocity; Bod | 2002 |
Dietary Mg(2+) supplementation restores impaired vasoactive responses in isolated rat aorta induced by chronic ethanol consumption.
Topics: Animals; Aorta, Thoracic; Atenolol; Blood Pressure; Body Weight; Dietary Supplements; Dose-Response | 2002 |
[Prazosin in the combined treatment of moderate to severe hypertension].
Topics: Adrenergic beta-Antagonists; Body Weight; Diuretics; Dizziness; Drug Therapy, Combination; Female; H | 1979 |
Effect of alpha 1-adrenoceptor blockade on the development of hypertension in the spontaneously hypertensive rat.
Topics: Adrenergic alpha-Antagonists; Animals; Biomarkers; Blood Pressure; Body Weight; Hemodynamics; Hypert | 1992 |
Enalapril reduces the enhanced 1,2-diacylglycerol content and RNA synthesis in spontaneously hypertensive rat hearts before established hypertension.
Topics: Animals; Body Weight; Cardiomegaly; Diglycerides; Enalapril; Heart Ventricles; Hypertension; Lipids; | 1992 |
Neonatal prazosin exposure reduces ovarian weight and estrogen receptor binding in adult female rats.
Topics: Animals; Animals, Newborn; Body Weight; Brain; Cytosol; Female; Male; Organ Size; Ovary; Prazosin; R | 1992 |
Antagonism of cocaine-induced fetal anomalies by prazosin and diltiazem in mice.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Cocaine; Diltiazem; Dose-Response Relationship, D | 1992 |
Postsynaptic alpha 1-blockade with terazosin does not modify insulin sensitivity in nonobese normotensive subjects.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Blood Glucose; Blood Pressure; Bod | 1991 |
Effects of the selective alpha 1-antagonist, doxazosin, on hepatic lipid levels and metabolism in the golden hamster.
Topics: Adrenergic alpha-Antagonists; Animals; Body Weight; Cholesterol; Cricetinae; Doxazosin; Hydroxymethy | 1991 |
Contractile responses and calcium mobilization in renal arteries of diabetic rats.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1991 |
Characterization of alterations of hemodynamics and neuroendocrine hormones in dexamethasone induced hypertension in dogs.
Topics: Animals; Blood Pressure; Body Weight; Cardiac Output; Dexamethasone; Dogs; Heart Rate; Hemodynamics; | 1991 |
Dietary sodium restriction and blood pressure response to sympathetic blockade in young versus adolescent spontaneously hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Body Weight; Clonidine; Diet, Sodium-Restrict | 1990 |
Increases in alpha-but not beta-adrenoceptors in hypertrophied non-infarcted cardiac muscles from rats with chronic myocardial infarction.
Topics: Animals; Body Weight; Cardiomegaly; Coronary Vessels; Dihydroalprenolol; Male; Muscle Proteins; Myoc | 1990 |
Diabetes-induced alteration in brain monoamine metabolism in rats.
Topics: Animals; Biogenic Amines; Blood Glucose; Body Weight; Brain; Choline O-Acetyltransferase; Diabetes M | 1986 |
Lack of cardiac alpha 1-adrenoceptor involvement in ethanol-induced cardiac hypertrophy.
Topics: Adrenal Glands; Animals; Behavior, Animal; Body Weight; Cardiomegaly; Catecholamines; Ethanol; Male; | 1989 |
Alpha-blockade on blood pressure and on cardiac noradrenaline content in SHR and DOCA-salt rats.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Body Weight; Desoxycorticosterone; Heart; Hyp | 1989 |
The effect of long-term administration of alpha 1-blocker prazosin on capillary density in cardiac and skeletal muscle.
Topics: Animals; Blood Pressure; Body Weight; Capillaries; Coronary Circulation; Coronary Vessels; Heart; He | 1989 |
The field-stimulated vas deferens of the streptozotocin-diabetic mouse: effects of prazosin, alpha, beta-methylene ATP, and variation of stimulation parameters.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Electr | 1989 |
Hypertensinogenic factors and renal alpha-adrenoceptors in young SHR and WKY rats.
Topics: Animals; Blood Pressure; Body Weight; Desoxycorticosterone; Hypertension; Kidney; Male; Prazosin; Ra | 1987 |
Combined neurohumoral block modulates pulmonary vascular P/Q relationship in conscious dogs.
Topics: Animals; Atropine; Autonomic Nervous System; Blood Pressure; Body Weight; Captopril; Cardiac Output; | 1988 |
Long-term experience with terazosin for treatment of mild to moderate hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Dru | 1986 |
Overall safety of terazosin as an antihypertensive agent.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Asthenia; Body Weight; Dizziness; Female; Hea | 1986 |
Postnatal treatment of rats with adrenergic receptor agonists or antagonists influences differentiation of sexual behavior.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Animals, Newborn; Body Weight; Clo | 1987 |
The influence of atenolol and prazosin on serum lipids and atherosclerosis in minipigs fed a hyperlipidemic diet.
Topics: Animals; Arteriosclerosis; Atenolol; Body Weight; Cholesterol, Dietary; Diet; Female; gamma-Glutamyl | 1988 |
Comparison of cicletanine with other antihypertensive drugs in SHR-SP models.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Captopril; Cardiomegaly; Diuresis; Di | 1988 |
Pre- and neonatal exposure of the Dahl rat to NaCl: development and regional distribution of myocardial alpha 1-adrenergic and cholinergic receptor sites.
Topics: Animals; Animals, Newborn; Blood Pressure; Body Weight; Cell Membrane; Female; Heart; Heart Atria; H | 1986 |
Hepatic adrenergic receptors in the genetically diabetic C57 BL/KsJ (db/db) mouse.
Topics: Animals; Body Weight; Cell Membrane; Diabetes Mellitus, Experimental; Dihydroalprenolol; Heterozygot | 1987 |